Substance P Antagonism Prevents Chemotherapy-Induced Cardiotoxicity

Substance P Antagonism Prevents Chemotherapy-Induced Cardiotoxicity

<i>Background</i>: Doxorubicin (DOX), used in chemotherapeutic regimens in many cancers, has been known to induce, cardiotoxicity and life-threatening heart failure or acute coronary syndromes in some patients. We determined the role of Substance P (SP), a neuropeptide and its high affin...

Full description

Bibliographic Details
Main Authors:	Ashiq Legi, Emma Rodriguez, Thomas K. Eckols, Cyrus Mistry, Prema Robinson
Format:	Article
Language:	English
Published:	MDPI AG 2021-04-01
Series:	Cancers
Subjects:	substance P chemotherapy associated cardiotoxicity
Online Access:	https://www.mdpi.com/2072-6694/13/7/1732

Similar Items

CHEMOTHERAPY CARDIOTOXICITY SCREENING WITH CARDIAC TROPONINS
by: O. V. Krikunova, et al.
Published: (2015-12-01)

Severe mitral regurgitation, an unusual manifestation of chemotherapy-induced cardiotoxicity
by: Ahmad Mirdamadi, et al.
Published: (2017-01-01)

Physiopathology and diagnosis of cardiotoxicity in patients submitted to chemotherapy treatment
by: Filipe C. Marmelo, et al.
Published: (2019-02-01)

Cardiotoxicity caused by gemcitabine
by: Yuri Isaakyan, et al.
Published: (2023-01-01)

Cardiotoxicity of doxorubicin – causes, prevention, prospects
by: Paweł Wesołowski, et al.
Published: (2022-11-01)

Biomarkers of chemotherapy-induced cardiotoxicity: toward precision prevention using extracellular vesicles
by: Brian B. Silver, et al.
Published: (2024-04-01)

Diagnosis of Chemotherapy-Induced Cardiotoxicity
by: Fausto Pizzino, et al.
Published: (2014-08-01)

Cardiovascular Magnetic Resonance in Early Detection of Radiation Associated Cardiotoxicity With Chest Radiation
by: Srilakshmi Vallabhaneni, et al.
Published: (2022-05-01)

Assessing cardiotoxicity in randomised trials of anthracycline chemotherapy
by: Kerr, A
Published: (2016)

Quantification of Extracellular Volume in CT in Neoadjuvant Chemotherapy in Breast Cancer: New Frontiers in Assessing the Cardiotoxicity of Anthracyclines and Trastuzumab
by: Marcello Chiocchi, et al.
Published: (2023-01-01)

The Value of Troponin as a Biomarker of Chemotherapy-Induced Cardiotoxicity
by: Victorita Sorodoc, et al.
Published: (2022-08-01)

Stratifying breast cancer patients by baseline risk of cardiotoxic complications linked to chemotherapy
by: Zhenisgul Tlegenova, et al.
Published: (2023-06-01)

Editorial: Cardiotoxicity induced by radiotherapy and/or chemotherapy after cancer treatment
by: Marjan Boerma, et al.
Published: (2022-11-01)

Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy
by: Yu. A. Vasyuk, et al.
Published: (2021-10-01)

Chemotherapy-induced cardiotoxic effect in breast cancer patients treated with trastuzumab (Herceptin) by MRI
by: Mohamed Aboulfotouh Mourad, et al.
Published: (2023-12-01)

3D-based strain analysis and cardiotoxicity detection in cancer patients received chemotherapy
by: Muhammad Azzam, et al.
Published: (2023-08-01)

Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
by: Alexandros Briasoulis, et al.
Published: (2022-02-01)

The puzzling clinical presentation of fluoropyrimidines cardiotoxicity
by: Linda Cucciniello, et al.
Published: (2022-09-01)

Potential Gene Association Studies of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis
by: Xinyu Yang, et al.
Published: (2021-06-01)

Circulating Biomarkers for Monitoring Chemotherapy-Induced Cardiotoxicity in Children
by: Luigia Meo, et al.
Published: (2023-11-01)

Protection against Doxorubicin-Induced Cardiotoxicity by Ergothioneine
by: Irwin K. Cheah, et al.
Published: (2023-01-01)

Case Series: Sacubitril/Valsartan Role for Chemotherapy-Induced Cardiotoxicity: An in-Depth Investigation in Saudi Arabia
by: Alshammari A, et al.
Published: (2024-01-01)

Left ventricular diastolic function and cardiotoxic chemotherapy
by: Haider Rashid, et al.
Published: (2024-04-01)

Review on the Role of Epigenetic Modifications in Doxorubicin-Induced Cardiotoxicity
by: Himani Kumari, et al.
Published: (2020-05-01)

Cardiotoxicity of Anticancer Therapeutics
by: Jerry Dong, et al.
Published: (2018-02-01)

Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer
by: Maria C. Arciniegas Calle, et al.
Published: (2018-10-01)

Efficacy and safety of cardioprotective drugs in chemotherapy-induced cardiotoxicity: an updated systematic review & network meta-analysis
by: Ali Mir, et al.
Published: (2023-02-01)

Evaluation of subclinical cardiotoxicity in patients with breast cancer and arterial hypertension in two regimens of anthracycline-containing chemotherapy
by: A A Avalyan, et al.
Published: (2018-12-01)

The combined role of NT-proBNP and LV-GLS in the detection of early subtle chemotherapy-induced cardiotoxicity in breast cancer female patients
by: Laila Sulaiman, et al.
Published: (2021-03-01)

Cardioprotection From Cardiotoxicity
by: Guilherme H. Oliveira, MD, MBA
Published: (2019-09-01)

Can Dietary Nutrients Prevent Cancer Chemotherapy-Induced Cardiotoxicity? An Evidence Mapping of Human Studies and Animal Models
by: Xin-Yu Zhang, et al.
Published: (2022-06-01)

Prevention and management of anthracycline induced cardiotoxicity: A review
by: Ian Osoro, et al.
Published: (2022-12-01)

The efficacy and safety of exercise regimens to mitigate chemotherapy cardiotoxicity: a systematic review and meta-analysis of randomized controlled trials
by: Ahmed Mazen Amin, et al.
Published: (2024-02-01)

Cardiotoxicity of lung cancer-related immunotherapy versus chemotherapy: a systematic review and network meta-analysis of randomized controlled trials
by: Chengwei Jin, et al.
Published: (2023-04-01)

Risk Factors for Anthracycline-Induced Cardiotoxicity
by: Shuo Qiu, et al.
Published: (2021-09-01)

Engineered biomaterial delivery strategies are used to reduce cardiotoxicity in osteosarcoma
by: Yulin Hou, et al.
Published: (2023-10-01)

Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis
by: Emma Rodriguez, et al.
Published: (2021-07-01)

Cancer therapy-induced cardiotoxicity: Review and algorithmic approach toward evaluation
by: K Purkayastha, et al.
Published: (2017-01-01)

Early Detection of Cardiotoxicity in patients receiving cancer Chemotherapy Using three-dimensional and Speckle Tracking Echocardiography
by: Hany H Ebaid, et al.
Published: (2020-01-01)

Early Diagnosis of Chemotherapy-Linked Cardiotoxicity in Breast Cancer Patients Using Conventional Biomarker Panel: A Prospective Study Protocol
by: Saule Balmagambetova, et al.
Published: (2022-11-01)